Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG

Key Points

• Citadel Advisors acquired 523,450 shares of Hemab Therapeutics in the second quarter, valued at approximately $19.2 million and representing about 1.12% of the company. Braidwell LP also established a new position worth roughly $5.9 million.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $51.40. Price targets range from $36 to $60, although Weiss Ratings issued a sell rating.
• Hemab reported quarterly EPS of -$0.80, missing the consensus estimate of -$0.63. The clinical-stage biotech focuses on therapies for serious bleeding and thrombotic disorders, and its shares recently opened at $44.41.

Citadel Advisors LLC acquired a new position in Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 523,450 shares of the company's stock, valued at approximately $19,226,000. Citadel Advisors LLC owned about 1.12% of Hemab Therapeutics as of its most recent SEC filing.

Separately, Braidwell LP purchased a new stake in Hemab Therapeutics in the second quarter valued at approximately $5,877,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on COAG shares. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a "buy" rating and a $36.00 price target for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an "outperform" rating and a $50.00 price objective on the stock. Weiss Ratings started coverage on shares of Hemab Therapeutics in a research note on Thursday, August 13th. They issued a "sell (d+)" rating on the stock. HC Wainwright boosted their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Hemab Therapeutics to a "hold" rating in a research report on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.40.

Insiders Place Their Bets

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the business's stock in a transaction on Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the acquisition, the insider owned 6,444,637 shares of the company's stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Hemab Therapeutics Price Performance

Shares of NASDAQ:COAG opened at $44.41 on Monday. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.00 and a 12-month high of $55.42. The firm has a 50 day moving average of $45.23. The firm has a market capitalization of $2.07 billion and a P/E ratio of -1.79.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). On average, equities research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.